Neurocrine Biosciences announced its executives will present at the Bank of America Health Care Conference on May 12, 2026, in Las Vegas. The presentation will be webcast live and available for replay on the company's website. Neurocrine is a biopharmaceutical company focused on developing treatments for neurological, endocrine, psychiatric, and immunological disorders, with several FDA-approved drugs and a strong pipeline. This event offers investors insight into the company's progress and future plans.
VYKAT XR (diazoxide choline) treatment demonstrated significant and lasting improvements in hyperphagia and behavioral symptoms in individuals with Prader-Willi syndrome (PWS) for up to three years. Participants who resumed VYKAT XR after a 16-week w...
Neurocrine Biosciences reported that CRENESSITY (crinecerfont) significantly improved hormone levels and reduced glucocorticoid doses in patients with classic congenital adrenal hyperplasia (CAH) due to 11β-hydroxylase deficiency, a rare form of CAH....
Neurocrine Biosciences announced two-year Phase 3 data from the CAHtalyst Pediatric study showing that CRENESSITY (crinecerfont) treatment slows bone age progression and improves predicted adult height in children with classic congenital adrenal hype...
Neurocrine Biosciences announced that two-year data from their Phase 3 CAHtalyst Adult study shows CRENESSITY (crinecerfont) improves cardiometabolic outcomes like insulin resistance, body weight, and bone health in adults with classic congenital adr...
